Breakthrough Gene Therapy Cures Fatal Canine Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a rare, fatal genetic disease affecting dogs, primarily males, caused by a mutation that prevents dystrophin protein production. This leads to progressive muscle tissue destruction, replaced by fibrous or fatty tissue, and severe symptoms like muscle weakening, gait changes, thickened tongue, difficulty swallowing, and poor growth. Over 50% of affected dogs traditionally succumb to the disease by six weeks of age. While Golden Retrievers are at high risk, other breeds like Labrador Retrievers, German Short-Haired Pointers, Weimaraners, and Corgis can also be affected.

Researchers at the University of Missouri School of Medicine, led by Dongsheng Duan, have developed a revolutionary gene therapy offering a cure. This innovative treatment uses a harmless, symptom-free virus to deliver a miniature version of the dystrophin gene, called a “microgene,” to every muscle in the dog's body. Dogs treated between 2 and 3 months of age, when symptoms typically begin, showed normal development by 6 to 7 months, highlighting the therapy's success and the importance of early intervention to prevent irreversible damage.

This gene therapy presents significant benefits, providing a safe and effective solution where traditional treatments like anabolic steroids proved largely unhelpful and stem cell therapy carried severe risks, including death from complications or anti-rejection drugs. The therapy effectively halts the progression of this previously incurable and fatal condition. While the disease is rare, and affected dogs often don't live to reproductive age, carriers of the X-linked gene should be sterilized to prevent hereditary transmission, though carrier identification remains a challenge.

(Source: https://www.barkandwhiskers.com/2015-12-30-nl-duchenne-muscular-dystrophy-gene-therapy/)